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INTRODUCTION
Prostate cancer is common in the West and is uniformly lethal once metastasized. Thus, there is growing interest in examining the genetic alterations in prostate cancer. Until recently, however, solid tumors such as prostate carcinoma was treated as a single amorphous entity. Genetic studies were uniformly performed on the entire tumor without regard to its components despite the fact that a few groups were quite aware of both epithelial and stromal components of tumors, and the cell biology of the tumor "microenvironment" has been described for the last 20 years. Thus, until now, when a genetic alteration, be it intragenic mutation, regional amplification, or deletion manifested by loss of heterozygosity of markers (LOH) is attributed to a prostate cancer, it is unclear if the alteration is actually occurring in the epithelial compartment, the surrounding stromal compartment or both. Recently, Moinfar and colleagues, using a limited subset of samples and markers, demonstrated that LOH of markers representing three chromosomal loci can occur in the stromal compartment of a small pilot series of invasive breast adenocarcinomas (1). Further, the PI has demonstrated LOH of a limited set of markers in the stroma of invasive breast adenocarcinomas (2) . More importantly, somatic intragenic mutations of TP53 and PTEN have been found in the stroma, but are mutually exclusive within any single compartment (3) . This has never been examined in prostate cancers. Nonetheless, the mechanisms, especially the genetic mechanisms, by which the different cells in the micro-environment interact with the epithelial component to initiate and/or promote tumor growth is not well understood. Thus, the overall hypothesis of the submitted proposal was that genetic changes in the stromal and epithelial compartment of prostate adenocarcinomas differentially contribute to tumor growth, such that they affect clinical outcomes differently. The hypothesis is to be addressed by two Objectives:
1. To determine the relative frequency of genetic alterations within the stromal versus epithelial compartment of human prostate adenocarcinomas and to build a genetic model for multistage stepwise carcinogenesis involving the epithelium and stroma in prostate cancer; 2. To determine the clinical consequences of genetic alterations within the stromal versus epithelial compartment of adenocarcinomas of the prostate.
BODY

Objective 1: To determine the relative frequency of genetic alterations within the stromal versus epithelial compartment of human prostate adenocarcinomas, and to build a genetic model for multistage stepwise carcinogenesis involving the epithelium and stroma in prostate cancer
To characterize global genomic alterations in prostate cancer stroma and epithelium, 381microsatellite LOH/AI genome scan of DNA derived from LCM-captured epithelium and stroma of 116 T any N any M 0 sporadic prostate cancers. 371 markers across all chromosomes, ranging from 7 on chromosome 22 to 31 on chromosome 1, were analyzed. 38,460 PCR-reactions (19, 639 for epithelium, 18,821 stroma) were informative for LOH/AI evaluation. 20,188 (52.5%) LOH/AI events [9,742 (49.6%) in epithelium, 10,446 (55.5%) stroma] occurred. Average LOH/AI frequencies over entire chromosomes ranged from 42% to 58% in epithelium and 51% to 69% in stroma.
Per chromosome, overall average LOH/AI frequency in the stroma was uniformly found to be higher than that in the epithelium, in contrast to breast cancer (4). A marginal model was used to compare LOH/AI frequencies between epithelium and stroma for each chromosome, yielding model-based estimates for the LOH/AI frequencies and a p-value for the comparison. Stromal LOH/AI frequencies were significantly higher than those in epithelium for 16 of the chromosomes at 0.05 significance level and for 13 chromosomes (1, 2, 3, 4, 5, 6, 11, 15, 16, 18, 19, 20, 22) after adjustment for multiple testing by using 0.05/23 (P<0.002) as the significance level. Chromosome-wise average LOH/AI frequencies in 13 chromosomes are higher in the stroma than in the epithelium. Model-based statistics revealed 16 markers in epithelium and 8 in stroma with significantly higher LOH/AI frequencies compared to other markers on the same chromosome. Informatics analysis and formal statistics indicated that the LOH/AI profile of epithelium and stroma from a single subject tended to be more similar than samples from different subjects, again, in contrast to sporadic breast cancers (4, 5) .
For details, please see prepared manuscript in Appendix.
Objective 2: To determine the clinical consequences of genetic alterations within the stromal versus epithelial compartment of adenocarcinomas of the prostate
By studying the distributions and correlations between compartment-specific genomic alterations and the 3 CPF, tumor size, tumor grade and regional lymph node (LN) status, we found tumor size and grade to be closely (positively) related. Samples with metastases to regional LN also tend to have higher grade and large size of tumors, but the number of such samples is small.
Hierarchical Clustering and Multi-dimensional Scaling of Compartment-Specific LOH/AI Profiles with Respect to CPF
To study the relationship between CPF at presentation and the overall LOH/AI pattern, 116 samples were clustered by combining the epithelial and stromal samples from each of the same subjects. In effect, each subject is considered to have one sample, with 371x2=742 distinct markers. We also performed multi-dimensional scaling combining epithelial and stromal samples of the same subject.
In another clustering analysis, only the markers found to have p<0.05 in the hotspot analysis with at least 5 informative cases were included. We focused on these important markers in order to reduce any potential noise in the data. Due to the strong evidence of similar LOH/AI between epithelium and stroma noted above, when a marker is included, both LOH/AI in the epithelium and in the stroma for this marker is used in the clustering.
By labeling information for each of the CPF in the clustering results above, we see evidence of a relationship between the overall LOH/AI pattern and tumor grade. To formally test these associations, we divide the samples based on the first branching in the hierarchical clustering and compare the two groups of samples by performing the rank sum test for tumor grade and tumor size and Fisher's exact test for LN status. The p-values for the clustering based on all markers (and clustering based on hotspots only) are tumor grade P=0.002 (0.003); tumor size P=0.028 (0.016); and LN status P=0.16 (0.041). Thus, we see highly significant associations between overall LOH/AI patterns and tumor grade, in particular. The significant association with tumor size may be due to the inter-dependent relationship between tumor size and tumor grade. The results also suggest that markers that are hotspots may be more relevant to CPF than merely all the other markers, and so, considering only these markers reduces the noise in the data, especially for LN status.
Association between Compartment-Specific LOH/AI and CPF
The average LOH/AI frequency across each chromosome, in carcinomatous epithelium and stroma, respectively, was then tested for its association with CPF. The chromosome-wise LOH frequencies were used because they carry more information than those for single markers. After adjusting for multiple testing to control for the overall type I error rate at 5%, we found that the only significant results are for the relationship between tumor grade (a binary variable indicating grade of 7 or higher) and LOH/AI at 6 chromosomes in epithelium (chromosomes 4, 5, 8, 14, 16, 18) and at 1 chromosome in stroma (chromosome 4). It should be noted that the association is significant for a number of additional chromosomes at the 0.05 level, and the results in the epithelium and the stroma are similar for many chromosomes.
To confirm the association between chromosome-wise LOH/AI frequencies and tumor grade, we performed further analysis based on logistic regression. Given the candidate chromosomes above, a stepwise model building procedure was used to construct a model, based on which the predicted probabilities of having a higher grade were calculated for all samples. The average predicted probabilities follow a consistent pattern over the entire range of actual tumor grade, although only the binary information of having a grade of at least 7 has been used in the model fitting. This strengthens the reliability of our finding. 
INTRODUCTION
Prostate cancer is one of the leading causes of cancer and cancer-related deaths among men in the United States and Western Europe. (6) Recent investigation has highlighted the tumor microenvironment in cancer progression. Genetic changes in tumor stroma have been reported for a few types of solid tumors,(1-3, 7-11) although only selected markers have been used in most of these studies assessing loss-of-heterozygosity (LOH)/allelic imbalance (AI).
In prostate cancer (CAP), it has been suggested that tumor microenvironment must play an important role from progression, including acquisition of androgen independence, to distant metastases. (12, 13) It has also been suggested that tumor-microenvironment interactions through diffusible soluble factors, such as TGF-beta, as well as the extracellular matrix (ECM) leads to the development of metastasis.(13) Furthermore, the possibility of epithelial-mesenchymal transition (EMT) has been proposed, (13) although there is controversy about this mechanism in cancer progression. (14, 15) Nonetheless, in CAP, little is known about the genetic basis of the microenvironment: only one report described genotypic heterogeneity in mesenchymal cells with a small number of markers. (11) Still, this suggested that genetic alterations in CAP stroma exist and may be biologically relevant.
Recent studies have suggested that carcinoma and adjacent stroma are all derived from a common progenitor cell. (8, 10) In contrast, however, we have found that the spectrum of genomic alterations is distinct in sporadic breast cancer and likely independent between the stroma and neoplastic epithelium, suggesting that both elements are clearly not derived from a common progenitor clone but rather undergo similar selective pressures, whether in the epithelial carcinoma or in the tumor microenvironment.(4) To clarify whether global genomic alterations do occur in the tumor stroma and epithelium in prostate carcinoma and to see if there is a different spectrum of LOH/AI from sporadic breast cancer, we performed a whole genome LOH/AI scan using 381-microsatellite markers. Importantly, we also sought to determine if compartment-specific LOH/AI can be correlated with presenting clinico-pathologic features (CPF).
MATERIALS AND METHODS
Patients
116 T any N any M 0 prostate carcinomas were obtained and analyzed in accordance with the respective institution's Human Subjects Protection Committees. All slides were re-reviewed by a single genito-urinary pathologist (PZ). Clinical information such as the presence of lymph node metastasis, tumor grade (Gleason score), and tumor size were noted (Table 1S) .
Laser Capture Microdissection (LCM) and Total Genome LOH/AI Scan
LCM was performed using the Arcturus PixCell II microscope (Arcturus Engineering Inc., Mountain View, CA) to isolate neoplastic epithelium and tumor stroma separately. (2-4, 7, 16) We captured stromal fibroblasts adjacent to malignant epithelium the tumor stroma) under direct microscopic observation. (2-4, 7, 16) Stromal fibroblasts resided in between aggregations of epithelial tumor cells or no more than 0.5 cm distant from a tumor nodule. LCM is able to control for proximity of stroma to carcinoma cells amongst all samples. While epithelial-stromal cell cross-contamination is a possibility, we utilized standard and well-worked out protocols to minimize this, as reported previously. (3, 4, 16, 17) Corresponding normal DNA for each case was procured from normal tissue, obtained a large distance from the tumor site or from a different tissue block containing only normal tissue (latter first choice). The different origins of the corresponding normal DNA had no effect on the frequency or pattern of LOH/AI. Genomic DNA was extracted as previously described, with the exception that incubation in proteinase K was done at 65 C for two days. 
Data Analysis
The dataset contains LOH status at 381 markers for 116 different samples, each with neoplastic epithelium, tumor stroma and normal tissue. Ten markers were never informative in at least one compartments, and excluded. Two types of marginal models were used, the first to estimate chromosome-wise average LOH probabilities and the second to detect elevated LOH frequency at a given marker. In the former, one model was fitted for each chromosome with only one regression coefficient (the intercept). In the latter, one model was fitted for each marker to data from the same chromosome, with the only term being the indicator for this marker and the significance of its coefficient tested using a Wald test. That is, the LOH frequency at this marker was compared to the average LOH frequency over the rest of the same chromosome. In all models, the compound symmetry working correlation structure was used. To account for a number of features of LOH/AI data such intra-sample correlations and informativeness that differs among markers and among samples, marginal models for correlated data and the GEE estimation method of Diggle et al. (19) were used, yielding more efficient inference than simple average LOH/AI frequencies, and without strong parametric assumptions. For each chromosome in each compartment, model-based estimates of marker-wise LOH/AI probabilities were obtained from fitting a marginal model that allows the LOH/AI probability of each marker to be distinct. Furthermore, to detect markers with elevated LOH/AI frequencies, for each marker in Wilcoxon rank sum test and Fisher's exact test, adjusting for multiple testing (Bonferroni method). A stepwise model building process for logistic regression was undertaken to confirm and further explore the relationships found to be statistically significant. All data analysis was done with the statistical package R, version 1.8.1.
RESULTS
Overall Marker-and Chromosome-wise LOH/AI Frequencies
371 markers across all chromosomes, ranging from 7 on chromosome 22 to 31 on chromosome 1, were analyzed. 38,460 PCR-reactions (19,639 for epithelium, 18,821 stroma) were informative for LOH/AI evaluation. 20,188 (52.5%) LOH/AI events [9,742 (49.6%) in epithelium, 10,446 (55.5%) stroma] occurred. Average LOH/AI frequencies over entire chromosomes ranged from 42% to 58% in epithelium and 51% to 69% in stroma.
Per chromosome, overall average LOH/AI frequency in the stroma was uniformly found to be higher than that in the epithelium (Fig. 1a) , in contrast to breast cancer.(4) A marginal model was used to compare LOH/AI frequencies between epithelium and stroma for each chromosome, yielding model-based estimates for the LOH/AI frequencies and a p-value for the comparison. Stromal LOH/AI frequencies were significantly higher than those in epithelium for 16 of the chromosomes at 0.05 significance level and for 13 chromosomes (1, 2, 3, 4, 5, 6, 11, 15, 16, 18, 19, 20, 22) after adjustment for multiple testing by using 0.05/23 (P<0.002) as the significance level ( Fig. 1b , Table 2 ).
Hierarchical Clustering and Multi-dimensional Scaling of LOH/AI Profile of CAP
Epithelium Compared to its Stroma
We then sought to determine whether the tumor microenvironment LOH/AI profiles were more similar to one another or whether each stromal LOH/AI profile is more similar to that of its corresponding carcinomatous epithelium. The dissimilarity between each pair of samples can be measured by the proportion of discordant LOH/AI, ie, the proportion of markers being LOH/AI in one sample and ROH in the other among all markers that are informative in both samples.
Hierarchical clustering and multi-dimensional scaling of all 232 samples (116 epithelial, 116 stromal) do not reveal any overall closeness amongst the profiles of the epithelial samples alone, nor for the profiles of the stromal samples alone. In contrast, LOH/AI profiles of the epithelium and corresponding stroma from the same subjects tend to cluster closely together (Fig. 2) . This closeness can be visualized by connecting each of such pairs of samples in the multi-dimensional scaling plot (Fig. 2) , in which the distance between two samples closely approximates their dissimilarity measure.
We then numerically studied the closeness of each corresponding epithelial and stromal sample pairs by comparing the percentages of discordant LOH/AI between paired epithelialstromal pairs compared to those between other (non-corresponding) pairs of samples (Fig. 3) .
The former have a mean of 38.5% (SD7.3%) whereas the latter has a mean 47.4% (SD 10.6%).
To formally test the hypothesis that epithelial and stromal samples from the same subject exhibit similar overall LOH/AI profiles, we compared the degree of similarity between paired epithelium/stroma samples with their similarities to other samples. Specifically, for each epithelium (or stroma) sample, we rank its numerical dissimilarity score to the corresponding stroma (or epithelium) sample relative to its dissimilarities to all other 231 samples. A rank of 1 indicates that its corresponding stroma is closer to its epithelium than to any other sample. All 232 ranks together (median=36.5), one for each sample, were then compared to their expected median value of 231/2=115.5 under the null hypothesis (i.e. paired epithelium and stroma samples are overall no more similar than other pairs of samples) using the non-parametric signed rank test. The null hypothesis was rejected at p= 3.4 x 10 -34 , indicating very strong evidence for similarity between paired epithelium and its corresponding stroma, in contrast to sporadic breast cancer samples.(4)
Markers with Compartment-Specific Elevated LOH/AI Frequencies in CAP and
Comparison with Sporadic Breast Cancer
A marker locus with elevated LOH/AI frequency compared to other markers on the same chromosome suggests a potential nearby tumor suppressor gene. When the frequency of LOH/AI at a marker is significantly higher than that of other markers along the same chromosome, the is operationally termed a "hotspot".(4) A statistical model that accounts for intra-sample correlations is used to test, for each marker, whether its marginal (averaged over the entire population of patients) LOH/AI frequencies are significantly higher than those of the other markers on the same chromosome (after averaging). This exercise was performed for the epithelium and stroma separately. To adjust for multiple testing, the Bonferroni method is applied that uses 0.05/371=0.00013 (instead of 0.05) as the significance level. To further reduce the chance of false positives, we also required the number of informative cases to be at least 14 to ensure that uniform (100%) LOH/AI purely by chance is extremely unlikely (probability less than 0.05/371=0.00013). We found 16 LOH/AI hotspots in the epithelium (Table 3a ) and 8 in the stroma amongst our CAP samples (Table 3b ). A simpler method by Miller et al. (18) was also used for these same comparisons, and the result is also significant (p<0.00013 [0.05/371]) for all 24 hotspots, thus strengthening our observations. Interestingly, 12 of 16 hotspots in epithelium also had significantly elevated LOH/AI frequencies in the stroma at the 0.003 [0.05/16] level, and 6 of 8 hotspots in stroma have significantly elevated LOH/AI frequencies in the epithelium (p=0.0063 [0.05/8]). The probabilities of these happening by chance, based on the hypergeometric distribution, are 2.3 x 10 -9 and 1.6 x 10 -4 , respectively. Therefore, our data suggest that the similarity of genome-wide LOH/AI profiles between each sample's carcinomatous epithelium and its corresponding stroma is, to a very high probability.
To compare the LOH/AI tumor stroma profiles between CAP and those of breast cancer samples, we looked at 57 marker loci previously found to be hotspots for sporadic breast cancer samples.(4) Of these 57 markers, 55 are among the 371 in the current study. It is noteworthy that 67.3% of these markers have p-values that are less than 0.05, a proportion significantly higher than the 30.7% of all the markers in the current study with such small p-values (Table 4 ). We then utilized Fisher's exact test to test the null hypothesis that these 55 previously found hotspots for sporadic breast cancers (epithelium and/or stroma) constitute a random sample of the 371 markers in terms of their evidence for hotspots, ie, that these are found by coincidence or chance.
We were able to reject the null hypothesis by finding a very strong indication (p=7.4 x 10 -9 ) that sporadic prostate and breast cancers share some common LOH/AI hotspots, which suggests the existence of important chromosomal regions common to the pathogenesis of at least these 2 types of solid tumors.
Clinico-Pathological Features (CPF)
Hierarchical Clustering and Multi-dimensional Scaling of Compartment-Specific LOH/AI
Profiles with Respect to CPF
To study the relationship between CPF at presentation and the overall LOH/AI pattern, 116 samples were clustered by combining the epithelial and stromal samples from each of the same subjects (Fig. 4) . In effect, each subject is considered to have one sample, with 371x2=742 distinct markers. We also performed multi-dimensional scaling combining epithelial and stromal samples of the same subject.
In another clustering analysis, only the markers found to have p<0.05 in the hotspot analysis with at least 5 informative cases were included (Fig. 5 ). We focused on these important markers in order to reduce any potential noise in the data. Due to the strong evidence of similar LOH/AI between epithelium and stroma noted above, when a marker is included, both LOH/AI in the epithelium and in the stroma for this marker is used in the clustering.
Association between Compartment-Specific LOH/AI and CPF
The average LOH/AI frequency across each chromosome, in carcinomatous epithelium and stroma, respectively, was then tested for its association with CPF. The chromosome-wise LOH frequencies were used because they carry more information than those for single markers. After adjusting for multiple testing to control for the overall type I error rate at 5%, we found that the only significant results are for the relationship between tumor grade (a binary variable indicating grade of 7 or higher) and LOH/AI at 6 chromosomes in epithelium (chromosomes 4, 5, 8, 14, 16, 18) and at 1 chromosome in stroma (chromosome 4). It should be noted that the association is significant for a number of additional chromosomes at the 0.05 level, and the results in the epithelium and the stroma are similar for many chromosomes (Table 5 ).
To confirm the association between chromosome-wise LOH/AI frequencies and tumor grade, we performed further analysis based on logistic regression. Given the candidate chromosomes above, a stepwise model building procedure was used to construct a model, based on which the predicted probabilities of having a higher grade were calculated for all samples.
The average predicted probabilities follow a consistent pattern (Fig.6 ) over the entire range of actual tumor grade, although only the binary information of having a grade of at least 7 has been used in the model fitting. This strengthens the reliability of our finding.
DISCUSSION
Recent molecular studies have provided a myriad of information about genetic changes in prostate cancer. In epithelium, several candidate tumor suppressor genes in LOH/AI regions include NKX3.1 (located at 8p21), PTEN (10q23), CDKN1B (12p12), RB (13q14), and TP53 (17p13). (6, 20, 21) This is the first report investigating whole genome LOH/AI in prostate cancer stroma, ie, the prostate tumor microenvironment, and the first correlating global compartment-specific genomic alterations with CPF. Clustering methods and tests based on discordant LOH/AI percentages provide strong evidence for microenvironmental input in prostate cancer progression, possibly induced by EMT where one would expect the epithelial LOH/AI profile would be more in common with its corresponding stroma than any other sample.
That LOH/AI hotspots are similar in both compartments might suggest the presence of genes involved in EMT and/or a common progenitor stem cell which evolves into both carcinomatous epithelium and surrounding stroma. The most radical postulate, not inconsistent with our data, would be that it is the tumor microenvironment that undergoes the first genomic alterations. This is most likely true in breast cancers from individuals with BRCA1/2 germline mutation. (16) While this is plausible in breast cancers associated with initiating germline BRCA1/2 mutations, it is a little difficult to understand in the sporadic prostate carcinogenesis context.
In comparison with the LOH/AI spectra in the epithelium and stroma in sporadic breast cancer,(4) it is noteworthy that there are some common LOH/AI hotspots between breast and prostate cancers, reflecting the importance of these markers for solid tumor initiation or progression. Further, it is interesting that LOH/AI is more frequent in the stroma than in the epithelium in prostate cancer, whereas the average LOH/AI frequencies for all chromosomes at the individual marker level is higher in the epithelium than in the stroma in breast cancer. This difference may be due to the degree of EMT and/or a common stem cell progenitor which already possesses LOH/AI which develops into both the carcinomatous epithelum as well as the tumor stromal cells.
In conclusion, we have shown that overall LOH/AI is more frequent in stroma than epithelium in prostate cancers, and that LOH/AI profiles in the epithelium and stroma of each of the subjects cluster closely together, reflecting the importance of the microenvironment in initiation and progression. Finally, we demonstrated that overall genomic instability of chromosome 4 in the stroma and of 6 chromosomes in the neoplastic epithelium are associated with tumor grade, and by association, tumor size. This observation provides fundamental insight into chromosome-specific, compartment-specific roles in prostate carcinogenesis. Our data may also reveal the solid tumor microenvironment as a novel compartment for important biomarkers as well as targeted therapy. 
